These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3512191)

  • 21. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties.
    Holmer E; Söderberg K; Bergqvist D; Lindahl U
    Haemostasis; 1986; 16 Suppl 2():1-7. PubMed ID: 3744129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombin III and heparin.
    Barrowcliffe TW; Johnson EA; Thomas D
    Br Med Bull; 1978 May; 34(2):143-50. PubMed ID: 350337
    [No Abstract]   [Full Text] [Related]  

  • 23. Heparin.
    Thomas DP
    Clin Haematol; 1981 Jun; 10(2):443-58. PubMed ID: 7032783
    [No Abstract]   [Full Text] [Related]  

  • 24. From heparin to heparin fractions and derivatives.
    Coyne E
    Semin Thromb Hemost; 1985 Jan; 11(1):10-2. PubMed ID: 3883496
    [No Abstract]   [Full Text] [Related]  

  • 25. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
    Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The physiological inhibitors of blood coagulation. 1. Antithrombin III (AT III)].
    Kase F; Pospísil J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(3):337-49. PubMed ID: 6194066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physicochemical properties of heparin, and its interaction with Cu(II) and calcium in relation to anticoagulation.
    Stivala SS
    Fed Proc; 1977 Jan; 36(1):83-8. PubMed ID: 12019
    [No Abstract]   [Full Text] [Related]  

  • 28. Different pharmacokinetics, antithrombotic activity and bleeding effects of heparin and two new fragments administered in rat by subcutaneous route.
    Bergonzini GL; Bianchini P; Mascellani G; Osima B; Parma B; Volpi N
    Arzneimittelforschung; 1992 Nov; 42(11):1322-8. PubMed ID: 1337249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of complexes of heparin with plasma proteins on the anticoagulant and fibrinolytic activity of blood].
    Kudriashov BA; Pastorova VE; Liapina LA
    Fiziol Zh SSSR Im I M Sechenova; 1986 Dec; 72(12):1653-8. PubMed ID: 3817209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemistry and pharmacology of heparin.
    Ehrlich J; Stivala SS
    J Pharm Sci; 1973 Apr; 62(4):517-44. PubMed ID: 4121531
    [No Abstract]   [Full Text] [Related]  

  • 31. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 32. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J; Kumar A; Rock A; Walenga JM; Davis P
    Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
    Kaiser B; Hauptmann J; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombin-independent effects of heparins on fibrin clot nanostructure.
    Yeromonahos C; Marlu R; Polack B; Caton F
    Arterioscler Thromb Vasc Biol; 2012 May; 32(5):1320-4. PubMed ID: 22362760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mechanism of action of heparin].
    Collen D; Hoylaerts M; Lijnen HR
    Verh K Acad Geneeskd Belg; 1986; 48(1):33-49. PubMed ID: 3739420
    [No Abstract]   [Full Text] [Related]  

  • 36. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.
    Jeske W; Lormeau JC; Callas D; Iqbal O; Hoppensteadt D; Fareed J
    Semin Thromb Hemost; 1995; 21(2):193-200. PubMed ID: 7660142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation.
    Nordling S; Hong J; Fromell K; Edin F; Brännström J; Larsson R; Nilsson B; Magnusson PU
    Thromb Haemost; 2015 Jun; 113(6):1312-22. PubMed ID: 25740465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraprocedural stent thrombosis, antithrombin-III dependent heparin resistance and crush technique for bifurcation lesions: the "Devil's Triangle".
    Jao YT; Fang CC
    Int J Cardiol; 2015 Nov; 199():71-4. PubMed ID: 26188821
    [No Abstract]   [Full Text] [Related]  

  • 40. Heparin: biochemistry, therapy, and laboratory monitoring.
    Triplett DA
    Ther Drug Monit; 1979; 1(2):173-97. PubMed ID: 555571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.